Back to top

Image: Bigstock

Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Read MoreHide Full Article

Neurocrine Biosciences (NBIX - Free Report) reported $622.1 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 24.7%. EPS of $1.24 for the same period compares to $0.82 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $604.11 million, representing a surprise of +2.98%. The company delivered an EPS surprise of -15.65%, with the consensus EPS estimate being $1.47.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Product sales, net: $616.60 million compared to the $597.36 million average estimate based on 11 analysts. The reported number represents a change of +25.4% year over year.
  • Revenues- Collaboration revenue: $5.50 million versus the 10-analyst average estimate of $7.43 million. The reported number represents a year-over-year change of -21.4%.
  • Revenues- Product sales, net- INGREZZA: $612.90 million versus $596.27 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +26.1% change.
  • Revenues- Collaboration revenue- Royalty: $4.60 million versus $5.49 million estimated by four analysts on average.
  • Revenues- Product sales, net- Other: $3.70 million versus the two-analyst average estimate of $4 million.
View all Key Company Metrics for Neurocrine here>>>

Shares of Neurocrine have returned +1.8% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Neurocrine Biosciences, Inc. (NBIX) - free report >>

Published in